The FDA's critique of the anturane reinfarction trial.
D002986:Clinical Trials as Topic / Q000379:methods*; D003645:Death, Sudden / Q000209:etiology; D004311:Double-Blind Method; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010919:Placebos; D011897:Random Allocation; D012107:Research Design; D013442:Sulfinpyrazone / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D010919:Placebos; D013442:Sulfinpyrazone